ESMO Preceptorship on NSCLC, Singapore

Oncology Meeting Resources

15 Dec - 16 Dec, Singapore

ESMO Preceptorship

Main learning objectives for the ESMO Preceptorship on NSCLC, Singapore 2015 included learning about best clinical practice in the management of Non-Small Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic settings; understanding the importance of pathology and histoprognostic factors in the management of NSCLC; learning about the management of patients after progression, side‐effects of treatments, and the use of targeted agents in NSCLC 

Presentations from the Preceptorship are now available here. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

 

Useful Links

Presenter Presentation title Session title
J.Y. Douillard, FR State‐of‐the‐art: Standard of care for resectable NSCLC - Adjuvant chemotherapy Session 1 – Resectable NSCLC
D. Grunenwald, FR State‐of‐the‐art: Standard of care for resectable NSCLC - Surgical approach for resectable NSCLC Session 1 – Resectable NSCLC
K. Kerr, UK Histopathology of NSCLC, IHC markers and pTNM classification Session 1 – Resectable NSCLC
C. Le Pechoux, FR State-the-art for Locally Advanced unresectable/inoperable disease NSCLC: Update on RT/CT for unresectable NSCLC; Stereotactic RT and IMRT for inoperable NSCLC Session 2 – Unresectable locally advanced NSCLC
M. Reck, DE Is there a place for neoadjuvant treatment? Session 2 – Unresectable locally advanced NSCLC
P. Khullar, IN 62 year, diabetic Male, chronic smoker Session 3 - case discussion
A. Kurniawan, ID Issue Diagnostic in NSCLC Session 3 - case discussion
A. Batra, IN Metastatic Non-Small Cell Lung Cancer Session 3 - case discussion
F. Cappuzzo, IT 1st line chemotherapy and contribution of bevacizumab and impact of second-line chemotherapy in unselected patients Session 4 - Metastatic NSCLC
M. Reck, DE Maintenance treatment - Chemo maintenance or targeted agents or both? Session 4 - Metastatic NSCLC
T. Mitsudomi, JP Biomarkers driven treatment of selected NSCLC: ALK EML4; Crizotinib; Crizotinib resistance; 2nd generation drugs Session 5 - Biomarker driven treatment
J.Y. Douillard, FR Immunotherapy Session 5 - Biomarker driven treatment
Y.L. WU, CN Biomarker driven treatment of selected NSCLC: EGFR; EGFR TKI in mutant EGFR NSCLC; Mechanisms of resistance and drugs in development Session 5 - Biomarker driven treatment
M. Ahmad, IN Adenocarcinoma Lung – Driver mutation negative Session 6 - case discussion
S.L. Cyriac, IN EGFR TKIs and Brain metastases Session 6 - case discussion